Novocure’s Optune Now Available at More Than 600 Cancer Treatment Centers in the U.S.

Tuesday, September 22, 2020

Novocure™ (NASDAQ: NVCR) announced today that physicians at more than 600 cancer treatment centers in the U.S. have been certified to prescribe Optune to newly diagnosed and recurrent glioblastoma (GBM) patients.

Optune is Novocure’s wearable, portable, FDA-approved Tumor Treating Fields (TTFields) delivery system for the treatment of GBM. Physicians at an additional 350 medical institutions throughout the world also can prescribe Optune to GBM patients.

“We are proud to have certified physicians at a variety of cancer treatment centers, both large and small, in the community and academic settings, nationally and worldwide,” said Novocure’s CEO Asaf Danzinger. “It is our goal to bring our therapy to all GBM patients who can benefit from it. Optune is now more accessible to GBM patients than ever before, and we remain focused on broadening its reach.”

The latest physician certifications broaden the geographic reach of Optune in the community setting, making the therapy more accessible to patients.

Dr. Joseph C. Hodges, a radiation oncologist and certified Optune prescriber at Texas Oncology in Longview, Texas. said, “As a pioneer of community-based oncology, we strive to enhance patient access to innovative cancer treatments so patients can stay connected to the support of their families, friends and community during the challenging time of a cancer diagnosis.” Optune provides immense benefit to GBM patients, and we are excited to now offer this treatment to our patients,” concluded Hodges.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.